The activation mutation of serine threonine kinase v-RAF mouse sarcoma virus oncogene B1 (BRAF) is an important biomarker in human benign and malignant tumors, and most mutations affect BRAFV600 in exon 15 of BRAF gene (65). This evidence concerns the gene MARK2 and cancer.